# US 2021/0171487 A1 · Aromatic compound and preparation method therefor and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171487 A1
- Document ID: US20210171487A1
- Status: Published application
- Kind: A1
- Application number: 17/045,004
- Filed: 2019-04-04
- Published: 2021-06-10
- Earliest claimed: 2018-04-04
- Assignees: Shanghai Jianhe Pharmaceutical & Technology Co. Ltd.
- Applicants: Shanghai Jianhe Pharmaceutical & Technology Co. Ltd.
- Inventors: Tao XUE; Jing HUANG; Wenke WANG; Yilang CHEN
- Web page: https://patentgrep.com/patent/US20210171487A1

## CPC

- C07C 309/04: containing only one sulfo group
- C07D 309/30: Oxygen atoms, e.g. delta-lactones
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/133: having hydroxy groups, e.g. sphingosine
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/277: having a ring, e.g. verapamil
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07C 55/07: Salts thereof
- C07C 63/08: Salts thereof
- C07C 221/00: Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C 225/20: having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
- C07C 233/32: with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
- C07C 237/02: having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C 253/30: by reactions not involving the formation of cyano groups
- C07C 255/59: the carbon skeleton being further substituted by singly-bound oxygen atoms
- C07D 295/145: with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D 295/155: with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07B 2200/07: Optical isomers
- C07C 2601/08: the ring being saturated
- C07C 2601/14: The ring being saturated
- C07C 2601/18: with a ring being at least seven-membered
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to an aromatic compound and a preparation method therefor and the use thereof. Specifically, disclosed are a compound as shown in the following general formula (I), or a tautomer, an enantiomer, a diastereomer or a racemate thereof or a mixture thereof, or a pharmaceutically acceptable salt thereof. Also disclosed are a method for preparing the above compound and the use of same in the treatment of nervous system diseases.

## Claims

### Claim 1

A compound represented by the following general formula (I), or a tautomer, an enantiomer, a diastereomer, a racemate or a mixture thereof, or a pharmaceutically acceptable salt thereof;
wherein,
A is CH2 or O;
N1 and N2 are each independently 0, 1, 2, 3 or 4;
R1 and R2 are each independently hydrogen, C1-C6 alkyl or C1-C6 alkylcarbonyl, and the above-mentioned alkyl can be independently substituted by 1 to 2 substituents selected from the group consisting of halogen, hydroxyl, amino, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 ester, and C1-C4 amide;
R3 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy or halogen; and when A is CH2 and N1 is 1, R3 is not chlorine;
each R4 is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halogen, nitro, C1-C4 amide or cyano; and R3 and R4 are not hydrogen at the same time; or when R3 is fluorine, not all of the substituents at other positions of the benzene ring are hydrogen or position 5 of the benzene ring is not fluorine; and
the stereo configuration of α- or β-position carbon atom is each independently R, S or (R, S).

### Claim 2 (depends on 1)

The compound of claim 1, or a tautomer, an enantiomer, a diastereomer, a racemate or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound represented by general formula (I-A), (I-B) or (I-C):
general formula (I-A) compound
wherein, in formula (I-A), A, N1, N2, R3 and R4 are as defined in claim 1;
general formula (I-B) compound
wherein, in formula (I-B), A, N1, N2, R3 and R4 are as defined in claim 1, R1 and R2 are each independently hydrogen or C1-C6 alkyl, and the above alkyl can be independently substituted by 1 to 2 substituents selected from the group consisting of halogen, hydroxy, amino, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 ester, and C1-C4 amide;
general formula (I-C) compound
wherein, in formula (I-C), A, N1, N2, R3 and R4 are as defined in claim 1, R1 is C1-C6 alkylcarbonyl, and the above-mentioned alkyl can be independently substituted by 1 to 2 substituents selected from the group consisting of halogen, hydroxy, amino, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 ester, and C1-C4 amide.

### Claim 3 (depends on 1)

The compound of claim 1, or a tautomer, an enantiomer, a diastereomer, a racemate, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently hydrogen, methyl, ethyl or acetyl.

### Claim 4 (depends on 1)

The compound of claim 1, or a tautomer, an enantiomer, a diastereomer, a racemate, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein
R3 is hydrogen;
R4 is C1-C6 haloalkyl.

### Claim 5 (depends on 1)

The compound of claim 1, or a tautomer, an enantiomer, a diastereomer, a racemate, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein
R3 is halogen;
R4 is C1-C6 haloalkoxy.

### Claim 6 (depends on 1)

The compound of claim 1, or a tautomer, an enantiomer, a diastereomer, a racemate, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein R3 is hydrogen, fluorine, methyl, trifluoromethyl or trifluoromethoxy.

### Claim 7 (depends on 1)

The compound of claim 1, or a tautomer, an enantiomer, a diastereomer, a racemate, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein R4 is hydrogen, fluorine, chlorine, methyl, methoxy, trifluoromethyl, trifluoromethoxy or cyano.

### Claim 8 (depends on 1)

The compound of claim 1, or a tautomer, an enantiomer, a diastereomer, a racemate, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein the compound or a tautomer, an enantiomer, a diastereomer, a racemate or a mixture thereof, or a pharmaceutically acceptable salt thereof is selected from the group consisting of:

### Claim 9 (depends on 1)

A pharmaceutical composition which comprises a compound of claim 1, or a tautomer, an enantiomer, a diastereomer, a racemate or a mixture thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or excipient.

### Claim 10 (depends on 1)

Use of the compound of claim 1, or a tautomer, an enantiomer, a diastereomer, a racemate, or a mixture thereof, or a pharmaceutically acceptable salt thereof in the preparation of a medicine for the treatment of diseases related to the nervous system.

### Claim 11 (depends on 10)

The use of claim 10, wherein the diseases related to the nervous system is depression.

### Claim 12 (depends on 1)

A method for preparing a compound of claim 1, or a tautomer, an enantiomer, a diastereomer, a racemate or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein,
(1) the method comprises the steps:
wherein, A, N1, N2, R3 and R4 are as defined in claim 1;
a. compound I-1 is reacted with di-tert-butyl dicarbonate in a protic solvent or an aprotic solvent or a mixed solvent thereof to form compound I-2;
b. in an aprotic solvent, compound I-2 is reacted with trimethylchlorosilane to form compound I-3;
c. in an aprotic solvent, compound I-3 is oxidized by an oxidizing agent to form compound I-4;
d. in an aprotic solvent, a trimethylsilyl protecting group is removed from compound 1-4 to form compound I-5;
e. in a polar aprotic solvent, a tert-butoxycarbonyl protecting group is removed from compound I-5 to form compound I-A;
or
(2) the method comprises the steps:
wherein, A, N1, N2, R3 and R4 are as defined in claim 1, R1 and R2 are each independently hydrogen or C1-C6 alkyl, and the above-mentioned alkyl can be independently substituted by 1 to 2 substituents selected from the group consisting of halogen, hydroxy, amino, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 ester, and C1-C4 amide;
a. in a protic or an aprotic solvent or a mixed solvent thereof and in the presence of a catalyst and a hydrogen source, the compound I-A is reacted with an aldehyde to form compound I-B;
or
(3) the method comprises the steps:
wherein, A, N1, N2, R3 and R4 are as defined in claim 1, R1 is C1-C6 alkylcarbonyl, and the above alkyl can be independently substituted by 1 to 2 substituents selected from the group consisting of halogen, hydroxyl, amino, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 ester, and C1-C4 amide;
a. in an aprotic solvent, compound I-A is reacted with acyl chloride or acid anhydride to form compound III-1;
b. in a protic or an aprotic solvent or a mixed solvent thereof, compound III-1 is deprotected to form compound I-C.

### Claim 13 (depends on 1, 12)

The preparation method of claim 12, wherein:
the method for preparing compound I-1 comprises the steps:
wherein, in each formula, A, N1, N2, R3 and R4 are as defined in claim 1;
a. in an aprotic solvent, compound IV-1 is reacted with a nitrating reagent under the action of a catalyst to form compound IV-2;
b. in a protic or an aprotic solvent or a mixed solvent thereof, compound IV-2 is reduced by a metal reducing agent under the action of an organic or inorganic acid to form the compound I-1;
or
the method for preparing compound I-1 comprises the steps:
wherein, in each formula, A, N1, N2, R3 and R4 are as defined in claim 1;
a. in an aprotic solvent, compound IV-1 is reacted with a halogenated reagent to form compound V-1;
b. in an aprotic solvent, compound V-1 is reacted with an azide reagent to form compound V-2;
c. in a protic or an aprotic solvent or a mixed solvent thereof, compound V-2 is reacted in the presence of a catalyst and a hydrogen source to form compound I-1.

### Claim 14 (depends on 1, 13)

The preparation method of claim 13, wherein:
the method for preparing compound IV-1 comprises the steps:
wherein, in each formula, X can be H, Br or I; N1, N2, R3 and R4 are as defined in claim 1;
a. in an aprotic solvent, compound VI-1 is reacted with an epoxy compound VI-2 to form compound VI-3;
b. in an aprotic solvent, compound VI-3 is oxidized by an oxidizing agent to form the compound IV-1;
or
the method for preparing compound IV-1 comprises the steps:
wherein, in each formula, X can be Br or I; A, N1, N2, R3 and R4 are as defined in claim 1;
a. in an aprotic solvent, compound VI-1 is reacted with a cyclic ketone compound VII-1 under catalysis of a metal-containing catalyst and a phosphine-containing ligand to form compound IV-1.
